Boardroom Alpha
Boardroom Alpha
TNON · Revised Definitive Proxy Statement (DEFR14A) · Filed July 13, 2026

Tenon Medical Inc — Revised Definitive Proxy Statement (DEFR14A)

Form
DEFR14A
Filed
July 13, 2026
Ticker
TNON
Accession
0001213900-26-077492
About Tenon Medical Inc
Market cap
$4M
1Y TSR
−86.8%
3Y TSR
−79.4%
Board grade
D
Sector
Healthcare
CEO
Steven M Foster
Last annual meeting: Jul 23, 2026 · View full Tenon Medical Inc profile →

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

  

Schedule 14A

  

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No. 1)

 

Filed by the Registrant
Filed by a party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under Rule 14a-12

 

 

 

TENON MEDICAL, INC.

(Name of Registrant as Specified in its Charter)

 

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

TENON MEDICAL, INC.
104 Cooper Ct.
Los Gatos, CA 95032
(408) 649-5760
www.tenonmed.com

July 13, 2026

 

AMENDMENT TO THE PROXY STATEMENT

FOR THE ANNUAL MEETING OF STOCKHOLDERS OF

TENON MEDICAL, INC.

TO BE HELD ON THURSDAY, JULY 23, 2026

 

 

This amendment, dated July 13, 2026 (this “Amendment”), amends and supplements the definitive proxy statement on Schedule 14A, filed by Tenon Medical, Inc. (the “Company”) with the U.S. Securities and Exchange Commission on June 23, 2026 (as it may be amended, supplemented or otherwise modified from time to time, the “Proxy Statement”). Terms used in this Amendment that are not defined have the meaning given to them in the Proxy Statement. Except as described in this Amendment, the information provided in the Proxy Statement is not amended, supplemented or otherwise modified. THIS AMENDMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

 

This Amendment amends the Proxy Statement to correct inadvertent errors in the Proxy Statement regarding the required vote needed for approval of the Reverse Stock Split Proposal as follows:

 

1)The answer to a question “How many votes are needed to approve the other proposals” on page 6 of the Proxy Statement is amended and restated as follows (see underlined language):

 

“A: The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote is required to approve the Auditor Appointment Proposal, the Debt Financing Proposal and the Future Financings Proposal. Abstentions will be treated as votes against these proposals. The affirmative vote of a majority of the votes cast is required to approve the Adjournment Proposal; abstentions will have no effect on the Adjournment Proposal. The affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote is required to approve the Reverse Stock Split Proposal; abstentions and broker non-votes will have the same effect as votes against the Reverse Stock Split Proposal. Brokerage firms have discretionary authority to vote customers’ unvoted shares held in street name on the Auditor Appointment Proposal and the Reverse Stock Split Proposal, which are considered routine matters. Brokerage firms do not have authority to vote customers’ unvoted shares on the remaining proposals. If a broker does not exercise this authority on non-routine proposals, such broker non-votes will have no effect on the results of the vote on those proposals. We are not required to obtain the approval of our stockholders to appoint our independent registered public accounting firm. However, if our stockholders do not ratify the appointment of Haskell and White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, the audit committee of our Board (“Audit Committee”) will reconsider its appointment.”

 

2)The “Vote Required” subsection in the “Reverse Stock Split Proposal” section on page 33 is amended by replacing the words “outstanding stock entitled to vote” with “the voting power of the shares present or represented by proxy at the meeting and entitled to vote” as set forth below (see underlined language):

 

“The affirmative vote of a majority of the voting power of the shares present or represented by proxy at the meeting and entitled to vote is required for approval of the Reverse Stock Split Proposal.”

 

 

 

From this filing to the contest

Every contested election, re-scored daily.

Boardroom Alpha forecasts every contested situation and every director up for re-election. 0.88 AUC out-of-sample. Each contested forecast publishes as a long-form note you can hand to your IC.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Tenon Medical Inc (TNON)

Reference

Frequently asked questions

When did Tenon Medical Inc file this DEFR14A?
Tenon Medical Inc (TNON) filed this Revised Definitive Proxy Statement (DEFR14A) with the SEC on July 13, 2026. The accession number assigned by EDGAR is 0001213900-26-077492.
What does a DEFR14A disclose?
DEFR14A is a revised definitive proxy statement, filed when a company materially amends its earlier DEF 14A after distribution. Supersedes the prior proxy.
Where can I find Tenon Medical Inc's prior proxy contest filings on EDGAR?
The SEC EDGAR browser lists every DEFR14A Tenon Medical Inc has filed under CIK 1560293, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer